N. N. Blokhin National Research Medical Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia.
Clinical Department of Rostov State Medical University, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia.
Bull Exp Biol Med. 2020 Feb;168(4):503-506. doi: 10.1007/s10517-020-04741-9. Epub 2020 Mar 9.
Serum levels of glial fibrillar acidic protein (GFAP) were analyzed in 317 patients with primary and metastatic tumors of the brain, 78 patients with neurological diseases, and 66 normal subjects. A significant increase in the basal level of GFAP was typical of patients with glioblastomas in comparison with other groups (patients with astrocytomas, cerebral metastases, benign tumors, non-tumor diseases, and healthy subjects). An association of GFAP levels with unfavorable prognosis of overall survival in patients with glioblastoma was revealed. The data attest to high specificity and sensitivity of GFAP as a biochemical marker of glioblastoma.
在 317 例原发性和转移性脑肿瘤患者、78 例神经疾病患者和 66 例正常对照者中分析了神经胶质纤维酸性蛋白（GFAP）的血清水平。与其他组相比，胶质母细胞瘤患者的 GFAP 基础水平显著升高（包括星形细胞瘤患者、脑转移瘤患者、良性肿瘤患者、非肿瘤性疾病患者和健康受试者）。揭示了 GFAP 水平与胶质母细胞瘤患者总生存预后不良之间的关联。这些数据证明了 GFAP 作为胶质母细胞瘤的生化标志物具有很高的特异性和敏感性。
